Based on this feature, it circumvents significant thrombocytopenia due to concomitant inhibition of BCL-XL, making it clinically available for the treatment of AML, a disease typically associated with thrombocytopenia (57, 58). The gene discussed is BCL2L1; the disease is Thrombocytopenia.